glp-1 intracranial hypertension glp 1 idiopathic Idiopathic intracranial hypertension: Imaging and clinical fundamentals Infographic: Landmark trials in Neuro-Ophthalmology—results

Long-term considerations for semaglutide B12 therapy Semaglutide is not a short-term medication

After considering all of these factors, Rezaie and his colleagues found that patients using GLP-1RA medications had a statistically significant 33% higher chance of experiencing aspiration pneumonia than non-users (0.83% vs 0.63%) with a hazard ratio (HR) of 1.33

Always consult a licensed healthcare provider before starting semaglutide or any GLP-1 therapy

Cardiovascular benefit of oral semaglutide in patients with T2DM and established atherosclerotic cardiovascular diseases and/or chronic kidney disease is currently under investigation in SOUL (Semaglutide cardiovascular outcomes) trial (45)

The two drug classes (SGLT2 inhibitors and GLP-1RAs) differ largely in their pharmacological actions

The argument rests on the unusually broad distribution of GLP-1 receptors throughout the central nervous system